var data={"title":"Liothyronine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liothyronine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6468?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liothyronine-drug-information\" class=\"drug drug_general\">see &quot;Liothyronine: Drug information&quot;</a> and <a href=\"topic.htm?path=liothyronine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liothyronine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709013\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Weight reduction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines, such as those used for their anorectic effects.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189046\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cytomel;</li>\n      <li>Triostat</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189047\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cytomel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059834\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Thyroid Product</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443850\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Congenital hypothyroidism:</b> Oral: 5 mcg/day; increase by 5 mcg every 3 days to a maximum dosage of 20 mcg/day; <b>Note:</b> AAP recommends levothyroxine over liothyronine for treatment of hypothyroidism in neonates (AAP 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Postcardiac surgery replacement:</b> Very limited data available: Continuous IV infusion: 0.05 to 0.15 mcg/kg/<b>hour</b> adjusted to maintain a serum T<sub>3</sub> concentration 80 to 200 ng/dL; dosing based on experience in five neonates who, on postoperative days 0 to 2, required mechanical ventilation and exhibited total serum T<sub>3</sub> &lt;60 ng/dL (Chowdhury 2001; Dimmick 2008) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059826\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=liothyronine-drug-information\" class=\"drug drug_general\">see &quot;Liothyronine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Congenital hypothyroidism:</b><b>Note:</b> Guidelines do not recommend routine use of liothyronine over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]). Infants, Children, and Adolescents: Oral: 5 mcg/day; increase by 5 mcg every 3 to 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 20 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: 50 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;3 years and Adolescents: 25 to 75 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypothyroidism:</b> Oral: Initial: 25 mcg once daily; may increase by up to 25 mcg/day every 1 to 2 weeks; usual maintenance dose: 25 to 75 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients with cardiovascular disease:</i> Oral: Initial: 5 mcg once daily; may increase by 5 mcg/day every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients with myxedema:</i> Oral: Initial: 5 mcg once daily; increase in increments of 5 to 10 mcg/day every 1 to 2 weeks. When 25 mcg/day is reached, dosage may be increased at intervals of 5 to 25 mcg/day every 1 to 2 weeks. Usual maintenance dose: 50 to 100 mcg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to liothyronine from thyroid (desiccated) or levothyroxine:</i> Discontinue the other medication, initiate a low dose of liothyronine, and increase gradually according to response. Liothyronine has a rapid onset of action; residual effects of other thyroid preparation may persist for the first several weeks into therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myxedema coma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 25 to 50 mcg; patients with known or suspected cardiovascular disease: 10 to 20 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Normally, at least 4 hours should be allowed between IV doses to adequately assess therapeutic response and no more than 12 hours should elapse between doses to avoid fluctuations in hormone levels. Oral therapy should be resumed as soon as the clinical situation has been stabilized and the patient is able to take oral medication. If levothyroxine rather than liothyronine sodium is used in initiating oral therapy, the prescriber should bear in mind that there is a delay of several days in the onset of levothyroxine activity and that IV therapy should be discontinued gradually.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to liothyronine tablets from injectable liothyronine:</i> Discontinue the injectable, initiate oral therapy at a low dosage, and increase gradually according to response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>T<sub>3</sub> suppression test:</b> Oral: 75 to 100 mcg/day for 7 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189023\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triostat: 10 mcg/mL (1 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytomel: 5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytomel: 25 mcg, 50 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mcg, 25 mcg, 50 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189008\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059838\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Adults: IV: For IV use only; <b>do not administer SubQ or IM.</b> Administer at a rate of 10 mcg/minute (Gahart 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189040\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Vials must be stored under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Store tablets at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059837\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); as a pituitary thyroid-stimulating hormone (TSH) suppressant in the management or prevention of nontoxic goiter, thyroid nodules, subacute or chronic autoimmune thyroiditis (Hashimoto's), and multinodular goiter (FDA approved in adults); a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy (FDA approved in adults);<b><b>Note:</b></b> Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of myxedema coma/precoma (FDA approved in adults); has also been used for postcardiac surgery replacement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Clinical practice guidelines do not recommend routine use of liothyronine over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]). Guidelines do not recommend using TSH suppression for benign thyroid nodules in iodine sufficient patients (ATA [Haugen 2015]). May be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189090\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Liothyronine may be confused with levothyroxine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T3 is an error-prone abbreviation (mistaken as acetaminophen and codeine [ie, Tylenol&reg; #3])</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189089\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, hypotension, myocardial infarction, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Allergic skin reaction, angina pectoris, cardiac failure, fever, hypertension, phlebitis, twitching</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189030\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to liothyronine sodium or any component of the formulation; undocumented or uncorrected adrenal insufficiency; untreated thyrotoxicosis; artificial rewarming (injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Acute myocardial infarction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189012\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Treatment with glucocorticoids should precede thyroid replacement therapy in patients with adrenal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; they may be more likely to have compromised cardiovascular function. Increase dose slowly and monitor for signs/symptoms of angina.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight reduction (off-label use): <b>[US Boxed Warning]: Thyroid supplements are ineffective and potentially toxic for weight reduction.</b><b> High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022240\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause transient alopecia in children during first few months of therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299607\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189017\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12557&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189019\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189034\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liothyronine has not been found to increase the risk of teratogenic or adverse effects following maternal use during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy (Stagnaro-Green 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059833\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">T<sub>3</sub>, TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; growth, bone development (children); TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T<sub>4</sub> remains low and TSH is within normal limits, an evaluation of &quot;free&quot; (unbound) T<sub>4</sub> is needed to evaluate further increase in dosage. Free T<sub>4</sub> (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T<sub>4</sub>. During the first 3 years of life, total- or free-T<sub>4</sub> should be maintained in the upper <sup>1</sup>/<sub>2</sub> of the normal range; this should result in normalization of the TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of in utero hypothyroidism. Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation and accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Monitor TSH and total or free T<sub>4</sub> at 2 and 4 weeks after starting treatment, every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adults: Monitor TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (ATA [Jonklaas 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059836\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Thyroid Function Tests</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Lab Parameters</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Normal Range</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>4</sub> (thyroxine) serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.1-20.9 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8-14 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.8-16.6 mcg/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 month to 1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.5-16.0 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.0-12.0 mcg/dL </p></td></tr>\n        <tr>\n          <td rowspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">Free thyroxine index (FTI) </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.3-26.6 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 weeks </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.6-20.8 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.4-17.9 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4-12 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.1-14.5 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7-13.3 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.8-14.0  </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Newborns</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-470 ng/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-5 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-260 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-10 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90-240 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 years to Adult </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70-210 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> uptake</p></td>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35%-45% </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">TSH serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Cord</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-22 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;40 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;25 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0-10 micro international units/mL </p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189011\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189029\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak response: 2 to 3 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (95% in 4 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.75 days (Brent 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059843\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">For purposes of conversion, levothyroxine sodium (T<sub>4</sub>) 100 mcg is usually considered equivalent to desiccated thyroid 60 to 65 mg (1 grain), thyroglobulin 60 to 65 mg (1 grain), or liothyronine sodium (T<sub>3</sub>) 25 mcg. However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A synthetic form of <i>L</i>-Triiodothyronine (T<sub>3</sub>) can be used in patients allergic to products derived from pork or beef.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189033\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Liothyronine Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/mL (1 mL): $462.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Triostat Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/mL (1 mL): $493.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cytomel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg (100): $230.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (100): $302.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $461.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Liothyronine Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg (100): $80.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (100): $105.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $160.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189035\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cynomel (BF, BJ, CI, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, PE, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Cytomel (BB, BE, LU, NL);</li>\n      <li>Cytomel 25 (IL);</li>\n      <li>Dispon (IT);</li>\n      <li>Halotri (ES);</li>\n      <li>Iobolin (BR);</li>\n      <li>Liothyronin (NO, PL, SE);</li>\n      <li>Neo-Tiroimade (PT);</li>\n      <li>Novotiral (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>T3 (GR, PY);</li>\n      <li>Tertroxin (AU, CZ, GB);</li>\n      <li>Tetronine (KR);</li>\n      <li>Thybon Henning (DE);</li>\n      <li>Thyronine (JP);</li>\n      <li>Thyrotardin inject. (DE);</li>\n      <li>Ti-Tre (IT);</li>\n      <li>Tri-Iodo-Tironina (AR);</li>\n      <li>Trijodthyronin (AT, PL);</li>\n      <li>Trijodthyronin BC (DE);</li>\n      <li>Triyodotironina (ES);</li>\n      <li>Triyotex (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, &quot;Update of Newborn Screening and Therapy for Congenital Hypothyroidism,&quot;<i> Pediatrics</i>, 2006, 117(6):2290-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-pediatric-drug-information/abstract-text/16740880/pubmed\" target=\"_blank\" id=\"16740880\">16740880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent GA, Koenig RJ. Chapter 39. Thyroid and Anti-Thyroid Drugs. In: Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chowdhury D, Ojamaa K, Parnell VA, et al, &quot;A Prospective Randomized Clinical Study of Thyroid Hormone Treatment After Operations for Complex Congenital Heart Disease,&quot;<i> J Thorac Cardiovasc Surg</i>, 2001, 122(5):1023-5<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-pediatric-drug-information/abstract-text/11689811/pubmed\" target=\"_blank\" id=\"11689811\">11689811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytomel (liothyronine sodium) [prescribing information]. New York, NY: Pfizer; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimmick S, Badawi N, Randell T. Thyroid hormone supplementation for the prevention of morbidity and mortality in infants undergoing cardiac surgery (review).<i> Cochrane Database Syst Rev</i>. 2008;2:1-25.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL, Nazareno AR. <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>. 30th ed. St Louis, MO: Elsevier/Mosby; 2014, 745-47.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-pediatric-drug-information/abstract-text/23246686/pubmed\" target=\"_blank\" id=\"23246686\">23246686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-pediatric-drug-information/abstract-text/26462967/pubmed\" target=\"_blank\" id=\"26462967\">26462967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. <i>Thyroid</i>. 2014;24(12):1670-1751. doi: 10.1089/thy.2014.0028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-pediatric-drug-information/abstract-text/25266247/pubmed\" target=\"_blank\" id=\"25266247\">25266247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum, Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. <i>Thyroid</i>. 2011;21(10):1081-1125. doi: 10.1089/thy.2011.0087.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liothyronine-pediatric-drug-information/abstract-text/21787128/pubmed\" target=\"_blank\" id=\"21787128\">21787128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triostat (liothyronine sodium) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; January 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12557 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709013\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189046\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F189047\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059834\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443850\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059826\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189023\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189008\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059838\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F189040\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059837\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189090\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189089\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189030\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189012\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022240\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299607\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189017\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F189019\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189034\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059833\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1059836\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189011\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F189029\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1059843\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189033\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189035\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12557|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liothyronine-drug-information\" class=\"drug drug_general\">Liothyronine: Drug information</a></li><li><a href=\"topic.htm?path=liothyronine-patient-drug-information\" class=\"drug drug_patient\">Liothyronine: Patient drug information</a></li></ul></div></div>","javascript":null}